Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of NR222 lyophilized RSV mRNA vaccine in adults aged 60 years and older
CTR20261965Phase 2Active
- Sponsor
- Namixin Biopharma
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NR222 in respiratory syncytial virus disease (RSV), sponsored by Namixin Biopharma. Started Jun 2026; status: active.
02
Drugs
NR222
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20261965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261965.